EOM Pharmaceuticals Holdings, Inc. (IMUC)

OTCMKTS · Delayed Price · Currency is USD
0.1000
-0.0164 (-16.35%)
Jul 24, 2025, 3:19 PM EDT
-16.35%
Market Cap12.65M
Revenue (ttm)n/a
Net Income (ttm)-5.13M
Shares Out126.50M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,153
Average Volume2,307
Open0.1000
Previous Close0.1000
Day's Range0.0837 - 0.1000
52-Week Range0.0123 - 0.2050
Beta0.77
RSI57.12
Earnings Daten/a

About IMUC

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for th... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Employees 4
Stock Exchange OTCMKTS
Ticker Symbol IMUC
Full Company Profile

Financial Performance

Financial Statements

News

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

MONTVALE, N.J. , Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.

1 year ago - PRNewsWire

EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil

Results indicate that EOM613 treatment mitigates cytokine release in patients with COVID-19 pulmonary vascular inflammation MONTVALE, N.J. , Sept. 6, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, ...

2 years ago - PRNewsWire

EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement

MONTVALE, N.J. and LOS ANGELES, Dec. 2, 2021 /PRNewswire/ -- EOM Pharmaceuticals, Inc. ("EOM"), a privately held, clinical-stage pharmaceutical company, and ImmunoCellular Therapeutics, Ltd.

3 years ago - PRNewsWire

ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market

LOS ANGELES, June 28, 2021 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that the Company has taken steps to comply with amended Rule 15c2-11 under ...

4 years ago - PRNewsWire